Drugs / rE-4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03239119 | Nov 2017 → Dec 2018 | type 2 diabetes mellitus | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rE-4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03239119 ↗ |
| Route | Subcutaneous | “All are subcutaneously injected twice daily” NCT03239119 ↗ |